Erlotinib in Treating Patients With Advanced Kidney Cancer
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for
tumor cell growth.
PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have
advanced kidney cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio